| Literature DB >> 31947628 |
Elena Fornari1, Anita Morandi1, Claudia Piona1, Mara Tommasi1, Massimiliano Corradi1, Claudio Maffeis1.
Abstract
The aim of this study is to test the hypothesis that the intake of Policaptil Gel Retard® (PGR) is able to affect appetite, metabolic and hormonal postprandial profile in obese children. 46 obese children were randomly assigned to treatment with PGR or placebo, in a double blind clinical trial. Two PGR tablets or placebo were given in fasting condition, before the ingestion of a mixed meal (15 kcal/kg lean body mass). Blood samples were taken at baseline and for 4 hours, for measuring blood lipids, glucose, insulin, ghrelin, and glucagon like peptide-1 (GLP-1). Appetite was quantified using a visual analog scale. Children assuming PGR had a significantly lower increase of postprandial triglycerides (area under the curve (AUC): 3021 (2879) vs. 5038 (3738) mg × 240 min/Dl) and appetite (-234 (274) vs. 36 (329)) than children assuming placebo. The AUC of ghrelin was significantly lower after PGR ingestion, than after placebo (-8179 (8073) vs. -2800 (7579) pg × 240 min/mL). Blood glucose, insulin, non-esterified fatty acids (NEFA) and GLP-1 profiles were not significantly different in the two groups. In conclusion, a single intake of two tablets of PGR was associated with a significant reduction of appetite, ghrelin, and triglycerides in the postprandial period in obese children. Further investigation will assess if a chronic intake of PGR may affect body weight and glucose metabolism.Entities:
Keywords: appetite; children; fibers; ghrelin; obesity; postprandial phase; triglycerides
Year: 2020 PMID: 31947628 PMCID: PMC7019363 DOI: 10.3390/nu12010214
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Physical characteristics of the subjects and energy and macronutrient composition of the test meal.
| PGR ( | Placebo ( |
| |
|---|---|---|---|
| Physical Characteristics | |||
| Age (years) | 10.4 (1.1) | 9.8 (1.1) | ns |
| Gender (M/F) | 12/11 | 10/13 | ns |
| Weight (kg) | 56.1 (12.1) | 55.5 (14.5) | ns |
| Height (cm) | 147.4 (10.3) | 142.5 (10.0) | ns |
| BMI (kg × (m2)−1) | 25.6 (2.8) | 26.8 (4.0) | ns |
| BMI z-score | 1.68 (0.49) | 1.89 (0.53) | ns |
| WC (cm) | 83.5 (7.6) | 81.2 (11.7) | ns |
| WHtR | 0.57 (0.04) | 0.57 (0.06) | ns |
| Fat Mass (kg) | 19.1 (5.8) | 21.5 (8.1) | ns |
| Fat Mass (%) | 33.8 (5.9) | 37.8 (6.3) | ns |
| Fat free mass (kg) | 37.0 (7.9) | 33.9 (7.1) | ns |
|
| |||
| Total Energy (kcal) | 555.5 (119.3) | 509.0 (107.3) | ns |
| Carbohydrates (g) | 73.4 (17.1) | 67.3 (14.4) | ns |
| Carbohydrates (kcal) | 294.4 (63.2) | 269.7 (56.9) | ns |
| Carbohydrates (%) | 53.0 (11.4) | 53.0 (11.2) | ns |
| Protein (g) | 16.6 (3.9) | 15.2 (3.2) | ns |
| Protein (kcal) | 66.7 (14.3) | 61.1 (12.9) | ns |
| Protein (%) | 12.0 (2.5) | 12.0 (2.5) | ns |
| Fat (g) | 21.6 (5.0) | 19.8 (4.2) | ns |
| Fat (kcal) | 194.4 (41.7) | 178.1 (37.6) | ns |
| Fat (%) | 35.0 (7.5) | 35.0 (7.4) | ns |
Data shown as mean and standard deviation in brackets. Abbreviations: PGR, Policaptil Gel Retard; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio.
iAUCs of glucose, insulin, NEFA, GLP1, triglycerides, Ghrelin and appetite.
| iAUC | PGR ( | Placebo ( |
|
|---|---|---|---|
| Glucose (mg × 240 min/dL) | 3576 (2241) | 3022 (1524) | ns |
| Insulin (mU × 240 min/L) | 12,664 (15,047) | 13,366 (8351) | ns |
| NEFA (mmol × 240 min/L) | −67 (39) | −82 (37) | ns |
| GLP1 (pg × 240 min/mL) | −228 (4935) | 2586 (4418) | ns |
| Triglycerides (mg × 240 min/dL) | 3021 (2879) | 5038 (3738) | 0.046 |
| Ghrelin (pg × 240 min/mL) | −8179 (8073) | −2800 (7579) | 0.026 |
| Appetite (score) | −234 (274) | 36 (329) | 0.004 |
Data shown as mean and standard deviation in brackets. Abbreviations: iAUCs, incremental area under the curves; PGR, Policaptil Gel Retard; NEFA: non esterified fatty acids; GLP1: Glucagon-Like Peptide 1.
Figure 1Triglycerides serum concentration before and after the ingestion of PGR or placebo.
Figure 2Ghrelin serum concentration before and after the ingestion of PGR or placebo.
Figure 3Appetite visual analog scale scores before and after the ingestion of PGR or placebo.